ReviewCurrent hypertension reports2017
Resistant Hypertension: Mechanisms and Treatment.
Review in Current hypertension reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Aldosterone Synthase Inhibitors for Resistant Hypertension: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2025Pooled it
- Resistant hypertension: Epidemiology, mechanisms and contemporary therapeutic strategies.Heart international · 2026Review
- Endothelin Receptor Antagonists for the Treatment of Hypertension: Recent Data from Clinical Trials and Implementation Approach.Current cardiology reports · 2025Review
- Article
- Impact of Intermittent Hypoxia Related to Obstructive Sleep Apnoea Syndrome on Low-Grade Inflammation in Hypertensive Patients: Potential Implications for Cardiovascular Risk.Life (Basel, Switzerland) · 2024Article
- Review
- Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists.Future cardiology · 2024Review
- Associated factors and hemodynamic characteristics of resistant hypertension in the elderly.Journal of clinical hypertension (Greenwich, Conn.) · 2023Article
- Prevalence, Predictors, and Outcomes of Resistant Hypertension in Egyptian Population.Global heart · 2023Article
- Application of omics in hypertension and resistant hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- Renal NOXA1/NOX1 Signaling Regulates Epithelial Sodium Channel and Sodium Retention in Angiotensin II-induced Hypertension.Antioxidants & redox signaling · 2022Article
- Resistance to antihypertensive treatment and long-term risk: The Atherosclerosis Risk in Communities study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Managing Hypertension in the elderly: What's new?American journal of preventive cardiology · 2020Review
- Approaches for the Management of Resistant Hypertension in 2020.Current hypertension reports · 2020Review
- Resistant/Refractory Hypertension and Sleep Apnoea: Current Knowledge and Future Challenges.Journal of clinical medicine · 2019Review
- The Potential Role of Obstructive Sleep Apnoea in Refractory Hypertension.Current hypertension reports · 2019Review
- Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration-Approved Nanodrug Delivery Platforms.Hypertension (Dallas, Tex. : 1979) · 2019Review
- Apparent Treatment-Resistant Hypertension and Cardiovascular Risk in Hemodialysis Patients: Ten-Year Outcomes of the Q-Cohort Study.Scientific reports · 2019Article
- Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?Current hypertension reports · 2018Review
- Hypothalamic Ion Channels in Hypertension.Current hypertension reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewEmerging evidence suggests that multiple mechanisms may be responsible for the development of treatment-resistant hypertension (TRH). This review aims to summarize recent data on potential mechanisms of resistance and discuss current pharmacotherapeutic options available in the management of TRH. RECENT
findingsExcess sodium and fluid retention, increased activation of the renin-angiotensin-aldosterone system, and heightened activity of the sympathetic nervous system appear to play an important role in development of TRH. Emerging evidence also suggests a role for arterial stiffness and, potentially, gut dysbiosis. Therapeutic approaches for TRH should include diuretic optimization and the addition of aldosterone antagonists as the preferred fourth agent in most patients. Further therapeutic approaches may be guided by the suspected underlying mechanism of TRH in conjunction with other patient-specific factors. The pathophysiology of TRH is multifaceted; however, increasing evidence supports several mechanisms that may be targeted to improve blood pressure control among patients with TRH. Further studies are needed to determine whether such approaches may be more effective than usual care.
Indexed as
Identifiers
28597403What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.